Bernard Lerer - Böcker
Visar alla böcker från författaren Bernard Lerer. Handla med fri frakt och snabb leverans.
5 produkter
5 produkter
785 kr
Skickas inom 7-10 vardagar
Pharmacogenetics and pharmacogenomics are areas of significant importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This 2002 book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the established findings. Coverage extends to antipsychotics, antidepressants, mood stabilising, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore of interest to all clinicians and researchers working in this field.
2 677 kr
Tillfälligt slut
Pharmacogenetics and pharmacogenomics are areas of significant importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This 2002 book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the established findings. Coverage extends to antipsychotics, antidepressants, mood stabilising, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore of interest to all clinicians and researchers working in this field.
1 848 kr
Skickas inom 7-10 vardagar
This volume presents up-to-date, comprehensive and high quality reviews of the psychopharmacological evidence-base for each of the major psychiatric disorders, written by expert psychopharmacologists from around the world. Building on the success of the first edition, the volume summarizes the wealth of new developments in the field and sets them within the context of day-to-day clinical practice. All chapters have been fully updated and new contributions on personality disorders and substance dependence added. Each chapter provides information about optimal first line pharmacological interventions, maintenance pharmacotherapy and the management of treatment-refractory patients. The content is organized according to the DSM-V listing of psychiatric disorders, and covers all major conditions including schizophrenia, mood disorders, anxiety disorders, eating disorders and Alzheimer's disorder. These issues lie at the heart of clinical psychopharmacology, making this book invaluable to all practising and trainee clinicians, in a mental health setting or a less specialised environment.
902 kr
Skickas inom 7-10 vardagar
This volume presents up-to-date, comprehensive and high quality reviews of the psychopharmacological evidence-base for each of the major psychiatric disorders, written by expert psychopharmacologists from around the world. Building on the success of the first edition, the volume summarizes the wealth of new developments in the field and sets them within the context of day-to-day clinical practice. All chapters have been fully updated and new contributions on personality disorders and substance dependence added. Each chapter provides information about optimal first line pharmacological interventions, maintenance pharmacotherapy and the management of treatment-refractory patients. The content is organized according to the DSM-V listing of psychiatric disorders, and covers all major conditions including schizophrenia, mood disorders, anxiety disorders, eating disorders and Alzheimer's disorder. These issues lie at the heart of clinical psychopharmacology, making this book invaluable to all practising and trainee clinicians, in a mental health setting or a less specialised environment.
552 kr
Skickas inom 10-15 vardagar
This book is presented as a 1989 update on the task set by Robert Burton in his "Anatomy ofMelancholy," published in 1621. Burton's treatise addressed ques- tions regarding depression which are still highly relevant today: "...What is it, with all the kinds, causes, symptoms, prognostickes and several cures ofit..." These remain the core issues in affective disorders notwithstanding the remarkable progress that has been made in addressing them. New Directions in Affective Disorders sets out to provide an overviewofwhat has been achieved with particular emphasison developing trends and novel initiatives in bothfundamental research and treatment. The overriding objective of the book is to integrate significant contributions from basic and clinical science into a comprehensive format which will be of value to both clinicians and researchers. Intensive interest in affective illness isan inevitableconsequenceofthe frequency with which these disorders occur. Depression is the most common psychiatric condition, affecting as many as 50%ofpeople in Western countries at some time in their lives.National Institute ofMental Health Statistics estimate that 15% of adults between 18 and 74 years ofage may be suffering from serious depressive disorders in any given year. Depression is a serious condition with a high mortality. A suicide rate ofapproximately 20,000 deaths per year as a result of this illness is almost certainly a conservative estimate.